---
sidebar_position: 79
---
           <p class="stitle-article-norm">Recording and reporting of adverse events that occur during clinical investigations</p>
   <p class="norm">1.&nbsp;&nbsp;The sponsor shall fully record all of the following:</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any adverse event of a type identified in the 
clinical investigation plan as being critical to the evaluation of the 
results of that clinical investigation;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any serious adverse event;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(c)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any device deficiency that might have led to a 
serious adverse event if appropriate action had not been taken, 
intervention had not occurred, or circumstances had been less fortunate;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(d)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any new findings in relation to any event referred to in points (a) to (c).</p>
      </div>
   </div>
   <p class="norm">2.&nbsp;&nbsp;The sponsor shall report, without delay
 to all Member&nbsp;States in which the clinical investigation is being 
conducted, all of the following by means of the electronic system 
referred to in [[[Article&nbsp;73](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md):</p>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(a)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any serious adverse event that has a causal 
relationship with the investigational device, the comparator or the 
investigation procedure or where such causal relationship is reasonably 
possible;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(b)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any device deficiency that might have led to a 
serious adverse event if appropriate action had not been taken, 
intervention had not occurred, or circumstances had been less fortunate;</p>
      </div>
   </div>
   <div class="grid-container grid-list">
      <div class="list grid-list-column-1">
         <span>(c)&nbsp;</span>
      </div>
      <div class="grid-list-column-2">
         <p class="norm">any new findings in relation to any event referred to in points (a) and (b).</p>
      </div>
   </div>
   <p class="norm">The period for reporting shall take account of the 
severity of the event. Where necessary to ensure timely reporting, the 
sponsor may submit an initial report that is incomplete followed up by a
 complete report.</p>
   <p class="norm">Upon request by any Member&nbsp;State in which the 
clinical investigation is being conducted, the sponsor shall provide all
 information referred to in paragraph&nbsp;1.</p>
   <p class="norm">3.&nbsp;&nbsp;The sponsor shall also report to the 
Member&nbsp;States in which the clinical investigation is being 
conducted any event referred to in paragraph&nbsp;2 of this 
Article&nbsp;that occurred in third countries in which a clinical 
investigation is performed under the same clinical investigation plan as
 the one applying to a clinical investigation covered by this Regulation
 by means of the electronic system referred to in [[[Article&nbsp;73](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md).</p>
   <p class="norm">4.&nbsp;&nbsp;In the case of a clinical investigation
 for which the sponsor has used the single application referred to in 
[[Article&nbsp;78](../clinical evaluation and clinical investigationsArticle 78 - Coordinated assessment procedure for clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 78 - Coordinated assessment procedure for clinical investigations.md), the sponsor shall report any event as referred to in 
paragraph&nbsp;2 of this Article&nbsp;by means of the electronic system 
referred to in [[[Article&nbsp;73](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 73 - Electronic system on clinical investigations.md). Upon receipt, this report shall be 
transmitted electronically to all Member&nbsp;States in which the 
clinical investigation is being conducted.</p>
   <p class="norm">Under the direction of the coordinating 
Member&nbsp;State referred to in [[Article&nbsp;78](../clinical evaluation and clinical investigationsArticle 78 - Coordinated assessment procedure for clinical investigations.md)](../clinical evaluation and clinical investigationsArticle 78 - Coordinated assessment procedure for clinical investigations.md)(2), the 
Member&nbsp;States shall coordinate their assessment of serious adverse 
events and device deficiencies to determine whether to modify, suspend 
or terminate the clinical investigation or whether to revoke the 
authorisation for that clinical investigation.</p>
   <p class="norm">This paragraph&nbsp;shall not affect the rights of 
the other Member&nbsp;States to perform their own evaluation and to 
adopt measures in accordance with this Regulation in order to ensure the
 protection of public health and patient safety. The coordinating 
Member&nbsp;State and the Commission shall be kept informed of the 
outcome of any such evaluation and the adoption of any such measures.</p>
   <p class="norm">5.&nbsp;&nbsp;In the case of PMCF investigations 
referred to in [Article&nbsp;74](../clinical evaluation and clinical investigationsArticle 74 - Clinical investigations regarding devices bearing the CE marking.md)(1), the provisions on vigilance laid down
 in Articles&nbsp;87 to 90 and in the acts adopted pursuant to 
[Article&nbsp;91](../vigilanceArticle 91 - Implementing acts.md) shall apply instead of this Article.</p>
   <p class="norm">6.&nbsp;&nbsp;Notwithstanding paragraph&nbsp;5, this 
Article&nbsp;shall apply where a causal relationship between the serious
 adverse event and the preceding investigational procedure has been 
established.</p>